ReviewInternational journal of nephrology and renovascular disease2026
Salvianolic Acids and Their Pharmacological Promise in Kidney Diseases: A Narrative Review.
Review in International journal of nephrology and renovascular disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kidney disease is a major public health challenge, affecting millions of people worldwide. Conventional treatments often produce suboptimal outcomes and are associated with various adverse effects. Traditional Chinese Medicine has shown promising therapeutic potential, offering distinct advantages over conventional therapies for preventing and treating kidney diseases. Salvianolic acids, the principal bioactive constituents of Salvia miltiorrhiza, are widely used in the management of renal disorders. However, no dedicated review has systematically synthesized pharmacological evidence across different models of kidney disease. To advance both basic research and clinical applications, this review summarizes current knowledge on the therapeutic effects of salvianolic acids in acute kidney injury, diabetic kidney disease, and nephrotic syndrome. Their renoprotective actions arise from the modulation of multiple pathological processes, including inflammation, oxidative stress, apoptosis, mitochondrial dysfunction, endoplasmic reticulum stress, and autophagy dysregulation. Collectively, salvianolic acids hold promise as potential therapeutic agents for kidney diseases. Further studies are needed to confirm these molecular mechanisms and identify specific targets. Additionally, large-scale, long-term, multicenter clinical trials are crucial to evaluate the efficacy and safety of salvianolic acids in treating kidney diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.